Second malignancy in advanced or recurrent non-small cell lung cancer after the advent of molecular targeted drugs and immunotherapy.

IF 2.3 3区医学 Q3 ONCOLOGY Thoracic Cancer Pub Date : 2024-10-07 DOI:10.1111/1759-7714.15457

Yoshihiro Masui, Takehito Shukuya, Shunichi Kataoka, Hitomi Shiozaki, Kana Kurokawa, Ikuko Nakamura, Taichi Miyawaki, Yoshika Koinuma, Tetsuhiko Asao, Ryota Kanemaru, Shoko Sonobe Shimamura, Tomoyasu Mimori, Yoichiro Mitsuishi, Ken Tajima, Naoko Shimada, Kazuhisa Takahashi

{"title":"Second malignancy in advanced or recurrent non-small cell lung cancer after the advent of molecular targeted drugs and immunotherapy.","authors":"Yoshihiro Masui, Takehito Shukuya, Shunichi Kataoka, Hitomi Shiozaki, Kana Kurokawa, Ikuko Nakamura, Taichi Miyawaki, Yoshika Koinuma, Tetsuhiko Asao, Ryota Kanemaru, Shoko Sonobe Shimamura, Tomoyasu Mimori, Yoichiro Mitsuishi, Ken Tajima, Naoko Shimada, Kazuhisa Takahashi","doi":"10.1111/1759-7714.15457","DOIUrl":null,"url":null,"abstract":"Objectives: This study aimed to investigate the characteristics of patients with recurrent or advanced non-small cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors (TKIs) or immune-checkpoint inhibitors (ICIs) who developed secondary malignancies, as well as evaluate the impact of these secondary malignancies on the course of lung cancer.Materials and methods: This study included 112 patients with postoperative recurrent or advanced NSCLC, who received TKIs, ICIs, or immune combination therapy as the primary treatment modality between April 1, 2013, and March 31, 2020, and achieved long-term survival (≥2 years). Secondary malignancies were defined as newly diagnosed cancers in other organs occurring after NSCLC treatment initiation.Results: Among the 112 patients, 10 (8.9%) developed 12 carcinomas, including third primary malignancies. Univariate analysis, considering secondary malignancies as the outcome, revealed a non-significant trend towards a higher incidence of secondary malignancies in smokers compared to non-smokers.Conclusion: This study found that 8.9% of patients with advanced NSCLC who received TKIs, ICIs, or immune combination therapy and survived ≥2 years developed secondary malignancies. This underscores the importance of early diagnosis and treatment, even during lung cancer treatment, to identify suspicious lesions in other organs either via imaging or physical examinations.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.15457","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aimed to investigate the characteristics of patients with recurrent or advanced non-small cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors (TKIs) or immune-checkpoint inhibitors (ICIs) who developed secondary malignancies, as well as evaluate the impact of these secondary malignancies on the course of lung cancer.

Materials and methods: This study included 112 patients with postoperative recurrent or advanced NSCLC, who received TKIs, ICIs, or immune combination therapy as the primary treatment modality between April 1, 2013, and March 31, 2020, and achieved long-term survival (≥2 years). Secondary malignancies were defined as newly diagnosed cancers in other organs occurring after NSCLC treatment initiation.

Results: Among the 112 patients, 10 (8.9%) developed 12 carcinomas, including third primary malignancies. Univariate analysis, considering secondary malignancies as the outcome, revealed a non-significant trend towards a higher incidence of secondary malignancies in smokers compared to non-smokers.

Conclusion: This study found that 8.9% of patients with advanced NSCLC who received TKIs, ICIs, or immune combination therapy and survived ≥2 years developed secondary malignancies. This underscores the importance of early diagnosis and treatment, even during lung cancer treatment, to identify suspicious lesions in other organs either via imaging or physical examinations.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

分子靶向药物和免疫疗法出现后，晚期或复发性非小细胞肺癌的二次恶变。

研究目的本研究旨在调查接受酪氨酸激酶抑制剂（TKIs）或免疫检查点抑制剂（ICIs）治疗的复发性或晚期非小细胞肺癌（NSCLC）患者出现继发性恶性肿瘤的特征，并评估这些继发性恶性肿瘤对肺癌病程的影响：本研究纳入了112例术后复发或晚期NSCLC患者，这些患者在2013年4月1日至2020年3月31日期间接受了TKIs、ICIs或免疫联合疗法作为主要治疗方式，并获得了长期生存（≥2年）。继发性恶性肿瘤是指在NSCLC治疗开始后新诊断出的其他器官癌症：112名患者中，有10人（8.9%）罹患12种癌症，其中包括第三原发性恶性肿瘤。将继发性恶性肿瘤作为结果的单变量分析显示，吸烟者的继发性恶性肿瘤发病率高于非吸烟者，但这一趋势并不显著：本研究发现，在接受TKIs、ICIs或免疫联合疗法且存活≥2年的晚期NSCLC患者中，有8.9%的患者出现继发性恶性肿瘤。这强调了早期诊断和治疗的重要性，即使是在肺癌治疗期间，也要通过影像学检查或体格检查发现其他器官的可疑病变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.